Immunovant reported its third quarter fiscal year 2025 results, characterized by continued investment in clinical development and a significant financing event. The company is progressing its pipeline with key trial enrollments and data readouts expected in the latter half of 2026, while a substantial capital raise extends its cash runway through the potential launch of IMVT-1402 in Graves' disease.
Completed an underwritten financing generating approximately $550 million in gross proceeds, extending cash runway to potential launch of IMVT-1402 in GD.
positiveIMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in H2 2026.
positiveGeneral and administrative expenses decreased to $15.4 million from $19.8 million in the prior year quarter, driven by lower personnel and IT costs.
positiveNet loss improved slightly to $110.6 million from $111.1 million in the prior year quarter, with a narrower loss per share of $0.61 vs $0.76.
neutralResearch and development expenses increased to $98.9 million from $94.5 million year-over-year, primarily due to clinical trial activities and contract manufacturing costs.
attentionNon-GAAP R&D expenses increased to $91.1 million from $87.9 million year-over-year.
attentionNet loss for the nine months ended December 31, 2025 was $357.8 million, an increase from $307.4 million in the prior year period.
negativeStock-based compensation expense was $12.7 million for the quarter and $44.6 million for the nine months, contributing to net loss.
attentionMargin metrics will be available once backend extracts data from insights_json
The Company’s potentially registrational trial evaluating IMVT-1402 in D2T RA is fully enrolled, with topline data expected in the second half of calendar year 2026.
Other clinical development timelines remain on track for IMVT-1402 across previously announced indications, including potentially registrational trials in GD, MG, CIDP, and SjD, and a proof-of-concept trial in CLE.
In December 2025, the Company completed an underwritten financing with key institutional investors and Roivant, which generated approximately $550 million in gross proceeds, extending Immunovant’s cash runway to the potential launch of IMVT-1402 in GD.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.